Crescent BiopharmaCBIO +9.24%10 EBITDA Margin % is -2,234.74% as of Mar. 2026. GuruFocus rates CBIO with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, Crescent Biopharma ranks worse than 82.42% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Crescent Biopharma's EBITDA for the
three
months ended in Mar. 2026 was $-23.22 Mil. Crescent Biopharma's Revenue for the
three
months ended in Mar. 2026 was $1.04 Mil. Therefore, Crescent Biopharma's EBITDA margin for the quarter that ended in Mar. 2026 was -2,234.74%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Crescent Biopharma EBITDA Margin % Related Terms
Crescent Biopharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Crescent Biopharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CBIO vs RIGL, GYRE, TRAX: EBITDA Margin % Comparison
For the Biotechnology subindustry, Crescent Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescent Biopharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crescent Biopharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Crescent Biopharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescent Biopharma (CBIO) has a EBITDA Margin % of -2,234.74% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Crescent Biopharma and its competitors. According to the industry distribution chart, Crescent Biopharma ranks #778 out of 944 companies in the Biotechnology industry, placing it in the top 82.4%.
Is Crescent Biopharma's EBITDA Margin % too high?
Crescent Biopharma's current EBITDA Margin % is -2,234.74%. Based on the distribution chart, Crescent Biopharma ranks #778 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's EBITDA Margin % compare to RIGL and GYRE?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #778 out of 944 companies for EBITDA Margin %. This places Crescent Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current EBITDA Margin % is -2,234.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (CBIO) has a current EBITDA Margin % of -2,234.74%. The current EBITDA Margin % is -2,234.74%. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Crescent Biopharma (CBIO), the current EBITDA Margin % is -2,234.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score
Get the complete analysis for CBIO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBIO has been successfully added to your 